MDxHealth (MDXH)

Executive Summary

MDxHealth is a precision diagnostics company focused on improving the early detection of aggressive prostate cancer through its flagship product, the ExoDx Prostate Test. This non-invasive, urine-based test uses exosomal RNA analysis to assess a patient's risk of clinically significant prostate cancer, offering a convenient at-home collection option that eliminates the need for a digital rectal exam (DRE). The test is designed to reduce unnecessary biopsies, aligning with emerging urology trends toward value-based care. With FDA approval and commercialization underway, MDxHealth targets a large addressable market, given the high prevalence of prostate cancer screening. The company's recent addition of ExoDx to its menu strengthens its portfolio and provides a scalable platform for future liquid biopsy products. As a public company (NASDAQ: MDXH), MDxHealth has a market valuation of approximately $105 million and is focused on expanding its clinical adoption and reimbursement coverage.

Upcoming Catalysts (preview)

• Q3 2026Medicare Contractor LCD Update for ExoDx75% success
• Q4 2026NCCN Guideline Inclusion for ExoDx50% success
• Q1 2027European CE-IVD Expansion or Partnership65% success